Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Applied Health Economics and Health Policy
Published in: Applied Health Economics and Health Policy 1/2013

01-02-2013 | Correspondence

A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing

Authors: Brian Godman, Lars L. Gustafsson

Published in: Applied Health Economics and Health Policy | Issue 1/2013

Login to get access

Excerpt

We read the recent paper by Persson and colleagues with interest [1]. However, we think the paper contained some misunderstandings which we believe should be discussed further, as this paper is likely to be widely read both in Sweden and across Europe. …
Literature
1.
Persson U, Svensson J, Pettersson B. A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing. Appl Health Econ Health Policy. 2012;10:217–25.PubMedCrossRef
2.
Wettermark B, Godman B, Andersen K, et al. Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe. Pharmacoeconomics. 2008;26:537–50.PubMedCrossRef
3.
Godman B, Wettermark B, Hoffman M, Anderson K, Haycox A, et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev Pharmacoecon Outcomes Res. 2009;9:65–83.PubMedCrossRef
4.
Hugosson K, Engstrom A. Threshold value for a QALY: correlation with disease severity and decision uncertainty [abstract]. Value Health. 2008;11(3):A49.CrossRef
5.
Anell A, Persson U. Reimbursement and clinical guidelines for pharmaceuticals in Sweden: do health-economic evaluations support decision making? Eur J Health Econ. 2005;50:274–9.CrossRef
6.
7.
8.
Godman B, Bucsics A, Burkhardt T, Haycox A, Seyfried H, Wieninger P. Insight into recent reforms and initiatives in Austria: implications for key stakeholders. Expert Rev Pharmacoecon Outcomes Res. 2008;8:357–71.PubMedCrossRef
9.
Sermet C, Andrieu V, Godman B, Van Ganse E, Haycox A, Reynier JP. Ongoing pharmaceutical reforms in France: implications for key stakeholder groups. Appl Health Econ Health Policy. 2010;8:7–24.PubMedCrossRef
10.
Godman B, Paterson K, Malmstrom R, et al. Improving the managed entry of new drugs: sharing experiences across Europe. Expert Rev Pharmacoecon Outcomes Res. 2012;12:439–41.PubMedCrossRef
11.
12.
Kolaska K, Schubert S, Manca A, Hermanowski T. A review of health technology assessment (HTA) recommendations for drug therapies issued between 2007 and 2009 and their impact on policymaking processes in Poland. Health Policy. 2011;102:145–51.CrossRef
13.
Voncina L, Strizrep T. Croatia: 2009/2010 pharmaceutical pricing and reimbursement forum. Eurohealth. 2011;16:20–2.
14.
Wettermark B, Persson M, Wilking N, et al. Forecasting drug utilization and expenditure in a metropolitan health region. BMC Health Serv Res. 2010;10:128.PubMedCrossRef
15.
Godman B, Bennie M, Baumgärtel C, Sović Brkičić L, et al. Essential to increase the use of generics in Europe to maintain comprehensive healthcare? Farmeconomia Health Econ Ther Pathways. 2012;13(Suppl. 3):5–20.
16.
Godman B, Shrank W, Wettermark B, Andersen M, Bishop I, et al. Use of generics: a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals. 2010;3:2470–94. doi:10.​3390/​ph/​3082470.CrossRef
17.
Garuoliene K, Godman B, Gulbinovič J, Wettermark B, Haycox A. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Rev Pharmacoecon Outcomes Res. 2011;11:343–9.PubMedCrossRef
18.
van Woerkom M, Piepenbrink JF, Godman B, et al. Ongoing measures to enhance the efficiency of prescribing of PPIs and statins in the Netherlands: influence and future implications. J Comp Eff Res. 2012;1:527–38.
19.
Markovic-Pekovic V, Ranko Škrbić R, Godman B, Gustafsson LL. Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions. Expert Rev Pharmacoecon Outcomes Res. 2012;5:661–71.
20.
Bennie M, Godman B, Bishop I, Campbell S. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Rev Pharmacoecon Outcomes Res. 2012;12:125–30.PubMedCrossRef
21.
22.
Garuoliene K, Alonderis T, Marcinkevicius M. Pharmaceutical policy and the effects of the economic crisis: Lithuania. Eurohealth. 2011;17:1–4.
23.
Lexchin J, Kohler J. The danger of imperfect regulation: OxyContin use in the United States and Canada. Int J Risk Saf Med. 2011;23:233–40.PubMed
24.
Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt, et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilisation: changes seen and global implications. Expert Rev Pharmacoecon Outcomes Res. 2010;10:707–22.
25.
Vončina L, Strizrep T, Godman B, et al. Influence of demand side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future. Expert Rev Pharmacoecon Outcomes Res. 2011;11:469–79.PubMedCrossRef
26.
Norman C, Zarrinkoub R, Hasselström J, Godman B, Granath F, Wettermark B. Potential savings without compromising the quality of care. Int J Clin Pract. 2009;63:1320–6.PubMedCrossRef
27.
Gustafsson LL, Wettermark B, Godman B, Andersén-Karlsson E, Bergman U, et al. The “Wise List”: a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol. 2011;108:224–33.PubMedCrossRef
28.
Barrett A, Roques T, Small M, Smith R. How much will Herceptin really cost? BMJ. 2006;33:1118–20.CrossRef
29.
30.
Jaroslawski S, Toumi M. Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts. BMC Health Serv Res. 2011;11:259.PubMedCrossRef
31.
Adamski J, Godman B, Ofierska-Sujkowska G, Osinska B, Herholz H, et al. Review of risk sharing schemes for pharmaceuticals: considerations, critical evaluation and recommendations for European payers. BMC Health Serv Res. 2010;10:153. doi:10.​1186/​1472-6963-10-153.PubMedCrossRef
32.
Cheema PK, Gavura S, Migus M, Godman B, Yeung L, Trudeau M. International variability in the reimbursement of cancer drugs by publically funded drug programs. Curr Oncol. 2012;19:165–76. doi:10.​3747/​co.​19.​946.
33.
34.
Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med. 2012;366:864–6.PubMedCrossRef
Metadata
Title
A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing
Authors
Brian Godman
Lars L. Gustafsson
Publication date
01-02-2013
Publisher
Springer International Publishing AG
Published in
Applied Health Economics and Health Policy / Issue 1/2013
Print ISSN: 1175-5652
Electronic ISSN: 1179-1896
DOI
https://doi.org/10.1007/s40258-012-0008-7

Other articles of this Issue 1/2013

Applied Health Economics and Health Policy 1/2013 Go to the issue

Original Research Article

Assessing the Cost Utility of Response-Guided Therapy in Patients with Chronic Hepatitis C Genotype 1 in the UK Using the MONARCH Model

Editorial

Cost-Effectiveness Assessment of Orphan Drugs

Correspondence

Authors’ Reply to Godman and Gustafsson: “A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing”

Systematic Review

A Systematic Review of Economic Evaluations in Second and Later Lines of Therapy for the Treatment of Non-Small Cell Lung Cancer

Review Article

The Economic Evaluation of Medical Devices

Original Research Article

Cost-Effectiveness Analysis of Boceprevir for the Treatment of Chronic Hepatitis C Virus Genotype 1 Infection in Portugal